LRRK2 Antikörper (Glu519)

Produktnummer ABIN1882108

Produktdetails anti-LRRK2 Antikörper

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Bindungsspezifität: AA 504-536, Glu519

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LRRK2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. Purified Rabbit Polyclonal Antibody (Pab)

Immunogen: This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 504-536 amino acids from human PARK8(LRRK2).

Klon: RB7205

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 2 mg/mL

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Referenzen für anti-LRRK2 Antikörper (ABIN1882108)

Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

Details zu LRRK2

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Andere Bezeichnung: PARK8 (LRRK2) (LRRK2 Produkte)

Synonyme: LRRK2 antikoerper, AURA17 antikoerper, DARDARIN antikoerper, PARK8 antikoerper, RIPK7 antikoerper, ROCO2 antikoerper, 4921513O20Rik antikoerper, 9330188B09Rik antikoerper, AW561911 antikoerper, D630001M17Rik antikoerper, Gm927 antikoerper, cI-46 antikoerper, leucine-rich repeat kinase 2 antikoerper, leucine rich repeat kinase 2 antikoerper, lrrk2 antikoerper, LRRK2 antikoerper, Lrrk2 antikoerper

Hintergrund: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Synonyms: LRRK2, PARK8, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin

NCBI Accession: NP_940980

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development